← HALOZYME THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $146.7m | $316.6m | $151.9m | $196.0m | $267.6m | $443.3m | $660.1m | $829.3m | $1.0b | $1.4b | |
| Cost of Revenue | $33.2m | $31.2m | $10.1m | $45.5m | $43.4m | $81.4m | $139.3m | $192.4m | $159.4m | $228.8m | |
| Gross Profit (Calculated) | $113.5m | $285.5m | $141.7m | $150.4m | $224.2m | $361.9m | $520.8m | $636.9m | $855.9m | $1.2b | |
| Operating expenses: | |||||||||||
| Operating Income (Loss) | ($83.2m) | $81.0m | ($69.3m) | ($67.6m) | $144.3m | $275.9m | $267.5m | $337.6m | $551.5m | $469.0m | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | — | — | — | — | — | — | $43.1m | $73.8m | $71.0m | $76.7m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $6.4m | $160.9m | ($45.8m) | ($70.7m) | $130.4m | $248.1m | $248.9m | $348.8m | $557.9m | $467.5m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($101.9m) | $61.6m | ($79.8m) | ($72.3m) | $129.3m | $248.5m | $248.9m | $348.3m | $557.1m | $466.9m | |
| Investment Income, Net | $1.3m | — | — | — | — | — | — | — | — | — | |
| Net Income (Loss) Attributable to Parent | ($103.0m) | $63.0m | ($80.3m) | ($72.2m) | $129.1m | $402.7m | $202.1m | $281.6m | $444.1m | $316.9m | |
| Earnings Per Share, Basic | ($0.81) | $0.46 | ($0.56) | — | $0.95 | $2.86 | $1.48 | $2.13 | $3.50 | $2.64 | |
| Earnings Per Share, Diluted | ($0.81) | $0.45 | ($0.56) | ($0.50) | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 | |
| Weighted Average Number of Shares Outstanding, Basic | — | 136.4m | 143.6m | 144.3m | 136.2m | 140.6m | 136.8m | 131.9m | 126.8m | 119.8m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 139.1m | 143.6m | 144.3m | 141.5m | 146.8m | 140.6m | 134.2m | 129.4m | 123.9m | |
| Research and Development Expense | $150.8m | $150.6m | $150.3m | $140.8m | $34.2m | $35.7m | $66.6m | $76.4m | $79.0m | $284.9m | |
| Selling, General and Administrative Expense | $45.9m | $53.8m | $60.8m | $77.3m | $45.7m | $50.3m | $143.5m | $149.2m | $154.3m | $207.1m | |
| Other Nonoperating Income (Expense) | — | $2.6m | $7.6m | $7.0m | $5.4m | $1.1m | $1.0m | $16.3m | $23.8m | $21.5m | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $18.1m | $18.1m | |
| Costs and Expenses | $229.9m | $235.6m | $221.2m | $263.6m | $123.3m | $167.4m | $392.6m | $491.7m | $463.8m | $927.6m | |
| Interest Expense | $20.0m | $22.0m | $18.0m | $11.6m | $20.4m | $7.5m | $16.9m | $18.8m | $18.1m | $18.1m | |
| Interest Expense, Debt | $20.0m | — | — | — | $19.9m | — | — | — | — | — | |
| Operating Lease, Expense | — | — | — | — | — | $2.0m | $3.3m | $9.3m | $8.6m | $9.4m | |
| Income Tax Expense (Benefit) | $1.2m | ($1.4m) | $537k | ($11k) | $217k | ($154.2m) | $46.8m | $66.7m | $113.0m | $150.0m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.